TLRY Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -424.93% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -28.79% beat Edesa Biotech's return on equity of --.

Tilray Brands has a consensus price target of $1.22, signalling upside risk potential of 101.59%. On the other hand Edesa Biotech has an analysts' consensus of $10.33 which suggests that it could grow by 357.23%. Given that Edesa Biotech has higher upside potential than Tilray Brands, analysts believe Edesa Biotech is more attractive than Tilray Brands.

Tilray Brands has a beta of 1.817, which suggesting that the stock is 81.7% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.718%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Edesa Biotech quarterly revenues of --. Tilray Brands's net income of -$789.4M is lower than Edesa Biotech's net income of -$1.6M. Notably, Tilray Brands's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.63x versus 25.98x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -424.93% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -28.79% beat ESSA Pharma's return on equity of --.

Tilray Brands has a consensus price target of $1.22, signalling upside risk potential of 101.59%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -9.61%. Given that Tilray Brands has higher upside potential than ESSA Pharma, analysts believe Tilray Brands is more attractive than ESSA Pharma.

Tilray Brands has a beta of 1.817, which suggesting that the stock is 81.7% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.914%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than ESSA Pharma quarterly revenues of --. Tilray Brands's net income of -$789.4M is lower than ESSA Pharma's net income of -$6.4M. Notably, Tilray Brands's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.63x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -424.93% compared to Tilray Brands's net margin of -2177.64%. Tilray Brands's return on equity of -28.79% beat Lexaria Bioscience's return on equity of -147.06%.

Tilray Brands has a consensus price target of $1.22, signalling upside risk potential of 101.59%. On the other hand Lexaria Bioscience has an analysts' consensus of $6.33 which suggests that it could grow by 627.97%. Given that Lexaria Bioscience has higher upside potential than Tilray Brands, analysts believe Lexaria Bioscience is more attractive than Tilray Brands.

Tilray Brands has a beta of 1.817, which suggesting that the stock is 81.7% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.756%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Lexaria Bioscience quarterly revenues of $174K. Tilray Brands's net income of -$789.4M is lower than Lexaria Bioscience's net income of -$3.8M. Notably, Tilray Brands's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.63x versus 24.08x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -424.93% compared to Tilray Brands's net margin of -867.29%. Tilray Brands's return on equity of -28.79% beat Xenon Pharmaceuticals's return on equity of -31.52%.

Tilray Brands has a consensus price target of $1.22, signalling upside risk potential of 101.59%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $55.23 which suggests that it could grow by 74.68%. Given that Tilray Brands has higher upside potential than Xenon Pharmaceuticals, analysts believe Tilray Brands is more attractive than Xenon Pharmaceuticals.

Tilray Brands has a beta of 1.817, which suggesting that the stock is 81.7% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.839%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Xenon Pharmaceuticals quarterly revenues of $7.5M. Tilray Brands's net income of -$789.4M is lower than Xenon Pharmaceuticals's net income of -$65M. Notably, Tilray Brands's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.63x versus 175.06x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.